The 2024 meeting of the International AIDS Society (IAS), which is being held in Munich this week, began with the announcement of another curative bone marrow transplant. The new case brings the total number of patients cured of HIV via a bone marrow transplant up to 7 since “Berlin patient” Timothy Ray Brown became the first such person in 2007. Read More
Platycodin D (PD) is an oleanane-type triterpenoid saponin and one of the primary active substances isolated from the root of the Platycodon herb. Investigators from First Affiliated Hospital of Jinan University and affiliated organizations studied the effects of PD on high-fat diet-induced obesity and nonalcoholic fatty liver disease (now called metabolic dysfunction-associated steatotic liver disease or MASLD). Read More
Enanta Pharmaceuticals Inc. has patented compounds acting as nonstructural protein 3 (nsp3, PL-pro; SARS-CoV-2) inhibitors reported to be useful for the treatment of asthma, SARS-CoV-2 infection (COVID-19), rhinovirus, norovirus and lung infections. Read More
Many people living with HIV develop mild cognitive impairment and mood problems known as HIV-1-associated neurocognitive disorder (HAND). The activation of the cannabinoid CB1 receptor may be a feasible strategy to treat this disorder, but associated psychoactive side effects restrict their potential. Read More
From no hope to viable treatments, BioWorld is there to cover the breakthroughs in medicine. Listen to Randy Osborne explain why the BioWorld team is ‘always on the lookout for what's next.’ Read More
Zymeworks Inc. has received IND clearance from the FDA for ZW-191, the company’s novel folate receptor-α (FRα)-targeted topoisomerase I (TOPO1) inhibitor antibody-drug conjugate (ADC). Clinical development is set to begin this year, with filings to initiate studies outside the U.S. to be made in the second half of this year. Read More
Acrivon Therapeutics Inc. has identified new pyrimidine carboxamide compounds acting as Wee1-like protein kinase (Wee1) inhibitors potentially useful for the treatment of cancer. Read More
Jiangsu Vcare Pharmatech Co. Ltd. has created new proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety covalently linked to estrogen receptor α (ER-α)-binding moiety through a linker. They are reported to be useful for the treatment of cancer and infections. Read More
Epigenetic silencing could prevent the production of proteins that cause pathologies. CHARM (coupled histone tail for autoinhibition release of methyltransferase), a DNA methylation-based editor, suppressed transcription of prion proteins in the brains of mice. Read More
An Iongen Therapeutics Co. Ltd. patent reports transient receptor potential vanilloid 3 (TRPV3) receptor antagonists that are potentially useful for the treatment of acne, diabetes, anxiety, gastrointestinal, inflammatory and respiratory disorders, neurodegeneration and obesity, among others. Read More
Gluetacs Therapeutics (Shanghai) Co. Ltd. has synthesized oxoisoindolinyl substituted piperidinedione derivative molecular glue degraders characterized as IKZF1, IKZF3 and GSPT1 degradation inducers. They are reported to be useful for the treatment of cancer, anemia, liver failure, diabetes, infections, sarcoidosis, autoimmune diseases and cardiovascular disorders. Read More
Astellas Pharma Inc.’s subsidiaries Astellas Institute for Regenerative Medicine (AIRM) and Universal Cells Inc. have entered into a research collaboration with Osaka University to develop a pluripotent stem cell-derived cartilage organoid cell therapy for the treatment of intervertebral disc degenerative disease. Read More
